The global implantable neurostimulators market is estimated to be USD 5.54 billion in 2024 and is expected to reach USD 16.34 billion by 2035, with a CAGR of 10.33% during the forecast period 2025-2035. The market will grow due to factors such as the rising prevalence of neurological disorders, technological advancements in neurostimulation devices, favorable reimbursement policies and government support, and growing awareness and acceptance of neurostimulation therapies.
In November 2023, Boston Scientific announced the successful acquisition of Relievant Medsystems, Inc., incorporating its innovative Intracept Intraosseous Nerve Ablation System into its portfolio. This minimally invasive technology is specifically designed for managing chronic pain, aligning with the growing demand for less invasive treatment options in the global implantable neurostimulators market. The acquisition reflects Boston Scientific's commitment to advancing treatment solutions for chronic pain while addressing the increasing preference for minimally invasive procedures that offer improved patient outcomes and reduced recovery times.
By product type, the spinal cord stimulators segment accounted for the highest revenue-grossing segment in the global implantable neurostimulators market in 2024 owing to the rising prevalence of chronic pain conditions and increasing adoption of minimally invasive treatments that improve patient outcomes while reducing reliance on opioids. For instance, Valencia Technologies has reported that the recently revised clinical practice guideline on the diagnosis and treatment of idiopathic overactive bladder (2024) by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) recognizes implantable tibial nerve stimulation (ITNS) as a minimally invasive OAB treatment option. In the US, more than 1,100 patients are currently being treated with the eCoin ITNS system, which went on sale in March 2022. The expanding burden of an OAB population that is mostly underserved underscores the critical need for evolving treatment choices. Additionally, the deep brain stimulators segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of neurological disorders such as Parkinson's disease and essential tremor, coupled with advancements in personalized stimulation technologies and closed-loop systems.
By application, the pain management segment accounted for the highest revenue-grossing segment in the global implantable neurostimulators market in 2024 owing to the increasing burden of chronic pain disorders, favorable reimbursement policies, and growing awareness about neurostimulation as an effective alternative to pharmacological therapies. For instance, Medtronic plc, a world leader in healthcare technology, announced today in January 2024 that its PerceptTM RC Deep Brain Stimulation (DBS) system has been approved by the U.S. Food and Drug Administration (FDA). The newest addition to the Medtronic Percept™ family, which also includes the SenSight directional leads, BrainSense technology, and the Percept PC neurostimulator, is the rechargeable neurostimulator. Being the only sensing-enabled DBS system available, the Percept series enables doctors to customize treatment for patients with epilepsy and movement disorders such as essential tremor, Parkinson's disease, and dystonia. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to its expanding use in treating conditions like epilepsy, depression, and gastrointestinal disorders, supported by innovations in targeted neurostimulation technologies.
By end-user, the hospitals & ambulatory surgery centers (ASC) segment accounted for the highest revenue-grossing segment in the global implantable neurostimulators market in 2024 owing to the availability of advanced medical infrastructure, higher patient footfall, and skilled professionals for implantable neurostimulator procedures. For instance, at the American Society of Pain and Neuroscience (ASPN) Pain Conference in July 2024, ShiraTronics, a pioneer in clinical-stage neurostimulation, proudly shared the results of its Australian Pilot Study, RELIEV-CM. The world's first fully implantable neurostimulation system designed especially for chronic migraine is on display in this groundbreaking study. Additionally, the clinics & physiotherapy centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing accessibility of outpatient care, growing patient preference for cost-effective treatment options, and rising availability of neurostimulation therapies in non-hospital settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the strong healthcare infrastructure, high prevalence of chronic pain and neurological disorders, supportive reimbursement policies, and the presence of key players in the implantable neurostimulators market. For instance, the U.S. Food and Drug Administration (FDA) has approved the InceptivTM closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain, according to a statement released today by Medtronic plc, a global leader in healthcare technology, in April 2024. The closed-loop function of Inceptiv, the first Medtronic SCS device, monitors biological signals along the spinal cord and automatically modifies stimulation in real time to keep therapy in sync with everyday activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of advanced medical technologies, increasing healthcare expenditure, growing awareness of neurostimulation treatments, and a large patient population with unmet medical needs in countries like China and India.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
In November 2023, Boston Scientific announced the successful acquisition of Relievant Medsystems, Inc., incorporating its innovative Intracept Intraosseous Nerve Ablation System into its portfolio. This minimally invasive technology is specifically designed for managing chronic pain, aligning with the growing demand for less invasive treatment options in the global implantable neurostimulators market. The acquisition reflects Boston Scientific's commitment to advancing treatment solutions for chronic pain while addressing the increasing preference for minimally invasive procedures that offer improved patient outcomes and reduced recovery times.
By product type, the spinal cord stimulators segment accounted for the highest revenue-grossing segment in the global implantable neurostimulators market in 2024 owing to the rising prevalence of chronic pain conditions and increasing adoption of minimally invasive treatments that improve patient outcomes while reducing reliance on opioids. For instance, Valencia Technologies has reported that the recently revised clinical practice guideline on the diagnosis and treatment of idiopathic overactive bladder (2024) by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) recognizes implantable tibial nerve stimulation (ITNS) as a minimally invasive OAB treatment option. In the US, more than 1,100 patients are currently being treated with the eCoin ITNS system, which went on sale in March 2022. The expanding burden of an OAB population that is mostly underserved underscores the critical need for evolving treatment choices. Additionally, the deep brain stimulators segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of neurological disorders such as Parkinson's disease and essential tremor, coupled with advancements in personalized stimulation technologies and closed-loop systems.
By application, the pain management segment accounted for the highest revenue-grossing segment in the global implantable neurostimulators market in 2024 owing to the increasing burden of chronic pain disorders, favorable reimbursement policies, and growing awareness about neurostimulation as an effective alternative to pharmacological therapies. For instance, Medtronic plc, a world leader in healthcare technology, announced today in January 2024 that its PerceptTM RC Deep Brain Stimulation (DBS) system has been approved by the U.S. Food and Drug Administration (FDA). The newest addition to the Medtronic Percept™ family, which also includes the SenSight directional leads, BrainSense technology, and the Percept PC neurostimulator, is the rechargeable neurostimulator. Being the only sensing-enabled DBS system available, the Percept series enables doctors to customize treatment for patients with epilepsy and movement disorders such as essential tremor, Parkinson's disease, and dystonia. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to its expanding use in treating conditions like epilepsy, depression, and gastrointestinal disorders, supported by innovations in targeted neurostimulation technologies.
By end-user, the hospitals & ambulatory surgery centers (ASC) segment accounted for the highest revenue-grossing segment in the global implantable neurostimulators market in 2024 owing to the availability of advanced medical infrastructure, higher patient footfall, and skilled professionals for implantable neurostimulator procedures. For instance, at the American Society of Pain and Neuroscience (ASPN) Pain Conference in July 2024, ShiraTronics, a pioneer in clinical-stage neurostimulation, proudly shared the results of its Australian Pilot Study, RELIEV-CM. The world's first fully implantable neurostimulation system designed especially for chronic migraine is on display in this groundbreaking study. Additionally, the clinics & physiotherapy centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing accessibility of outpatient care, growing patient preference for cost-effective treatment options, and rising availability of neurostimulation therapies in non-hospital settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the strong healthcare infrastructure, high prevalence of chronic pain and neurological disorders, supportive reimbursement policies, and the presence of key players in the implantable neurostimulators market. For instance, the U.S. Food and Drug Administration (FDA) has approved the InceptivTM closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain, according to a statement released today by Medtronic plc, a global leader in healthcare technology, in April 2024. The closed-loop function of Inceptiv, the first Medtronic SCS device, monitors biological signals along the spinal cord and automatically modifies stimulation in real time to keep therapy in sync with everyday activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of advanced medical technologies, increasing healthcare expenditure, growing awareness of neurostimulation treatments, and a large patient population with unmet medical needs in countries like China and India.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Product Type, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Implantable Neurostimulators Market Report 2024 - 2035
Implantable Neurostimulators Market Analysis & Forecast by Product Type 2024 - 2035 (Revenue USD Bn)
- Spinal Cord Stimulators
- Deep Brain Stimulators
- Sacral Nerve Stimulators
- Vagus Nerve Stimulators
- Gastric Electrical Stimulation
Implantable Neurostimulators Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn)
- Pain Management
- Epilepsy
- Parkinson’s Disease
- Urinary and Fecal Incontinence
- Gastroparesis
- Others
Implantable Neurostimulators Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Hospitals & Ambulatory Surgery Centers (ASC)
- Clinics & Physiotherapy Centers
- Others
Implantable Neurostimulators Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Implantable Neurostimulators Market: Product Type Estimates & Trend Analysis
8. Implantable Neurostimulators Market: Application Estimates & Trend Analysis
9. Implantable Neurostimulators Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Implantable Neurostimulators Market
12. Europe Global Implantable Neurostimulators Market
13. Asia Pacific Global Implantable Neurostimulators Market
14. Latin America Global Implantable Neurostimulators Market
15. MEA Global Implantable Neurostimulators Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Medtronic Plc
- Boston Scientific Corporation
- AbbVie Inc.
- NeuroPace, Inc.
- Livanova PLC
- Johnson & Johnson (Ethicon)
- Stimwave, Inc.
- Nuvectra Corporation
- Baxter International Inc.
- Stryker Corporation
- Huntleigh Healthcare
- IMI (Inova Microelectronics Inc.)
- Zionexa
- NeuroSigma, Inc.
- Cochlear Ltd.
